Pre-order Enquiry
Request Free Sample
Global Cancer Monoclonal Antibodies Market Research Report 2021
SKU ID : QYR-17222485 | Publishing Date : 20-Jan-2021 | No. of pages : 98
The mAbs, which are produced by genetic engineering, target antigens in cells, tissues, and organs. They are used in clinical applications to treat diseases with excellent efficacy and minimal side effects. Their MOA, absence of generic pathway, and therapeutic applications distinguish them from other targeted therapeutics.
Cancer is one of the leading causes of death globally. There were 10.9 million new cases, in 2002, which increased to 14.1 million, in 2012 (approximately 30% growth in a decade). The WHO expects this number to increase by 70%, over the next two decades. According to the WHO, almost 70% of deaths occur in low and middle-income countries. The increment in data is expected to provide the basis for any national policy on cancer, leading to an increase in the percentage of people choosing cancer treatment. In the healthcare sector, cancer is one of the biggest concerns. Thus, the increased use of monoclonal antibodies for the treatment of cancer is driving this market.
The global Cancer Monoclonal Antibodies market was valued at US$ 34310 million in 2019 and is expected to reach US$ 63810 million by the end of 2026, growing at a CAGR of 9.2% during 2021-2026.
This report focuses on Cancer Monoclonal Antibodies volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Cancer Monoclonal Antibodies market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.
Global Cancer Monoclonal Antibodies Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
Murine Antibodies
Chimeric and Humanised Antibodies
Fully Humanized Antibodies
Others
Segment by Application
Liver
Breast
Blood
Brain
Hodgkins and Non-Hodgkins lymphoma
Colorectal
Leukaemia
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
By Company
F. Hoffmann-La Roche
Amgen
Bristol-Myers Squibb
Takeda Pharmaceuticals
Cancer is one of the leading causes of death globally. There were 10.9 million new cases, in 2002, which increased to 14.1 million, in 2012 (approximately 30% growth in a decade). The WHO expects this number to increase by 70%, over the next two decades. According to the WHO, almost 70% of deaths occur in low and middle-income countries. The increment in data is expected to provide the basis for any national policy on cancer, leading to an increase in the percentage of people choosing cancer treatment. In the healthcare sector, cancer is one of the biggest concerns. Thus, the increased use of monoclonal antibodies for the treatment of cancer is driving this market.
The global Cancer Monoclonal Antibodies market was valued at US$ 34310 million in 2019 and is expected to reach US$ 63810 million by the end of 2026, growing at a CAGR of 9.2% during 2021-2026.
This report focuses on Cancer Monoclonal Antibodies volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Cancer Monoclonal Antibodies market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.
Global Cancer Monoclonal Antibodies Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
Murine Antibodies
Chimeric and Humanised Antibodies
Fully Humanized Antibodies
Others
Segment by Application
Liver
Breast
Blood
Brain
Hodgkins and Non-Hodgkins lymphoma
Colorectal
Leukaemia
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
By Company
F. Hoffmann-La Roche
Amgen
Bristol-Myers Squibb
Takeda Pharmaceuticals
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
Request Sample
Request Discount
